A real-world analysis of FDA Adverse Event Reporting System (FAERS) events for liposomal nanoparticle-formulated and conventional anticancer irinotecan

Clinical & Translational Oncology 2026

View at publisher

Authors: Chunyong Xia, Jie Liu, Zhongyang Ren, Zhenming Cao

DOI: 10.1007/s12094-026-04247-2

Cited by: 1

References: 18

Fields of Study & Subjects

Cancer therapeutics and mechanisms Nanoparticle-Based Drug Delivery Statistical Methods in Clinical Trials

References 18